Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuen, Man-Fung | - |
dc.contributor.author | Plesniak, Robert | - |
dc.contributor.author | Lim, Seng Gee | - |
dc.contributor.author | Tsuji, Keiji | - |
dc.contributor.author | Diaconescu, Gheorghe | - |
dc.contributor.author | Gadano, Adrian | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Asselah, Tarik | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Heo, Jeong | - |
dc.contributor.author | Rizzardini, Giuliano | - |
dc.contributor.author | Janssen, Harry | - |
dc.contributor.author | Popescu, Corneliu Petru | - |
dc.contributor.author | Petrova, Diana | - |
dc.contributor.author | Wong, Alexander | - |
dc.contributor.author | Indriz, Nevin | - |
dc.contributor.author | Pojoga, Cristina | - |
dc.contributor.author | Tanaka, Yasuhito | - |
dc.contributor.author | Gusev, Denis | - |
dc.contributor.author | Janczewska, Ewa | - |
dc.contributor.author | Cremer, Jennifer | - |
dc.contributor.author | Elston, Robert | - |
dc.contributor.author | Lukic, Tamara | - |
dc.contributor.author | Maynard, Lauren | - |
dc.contributor.author | Kendrick, Stuart | - |
dc.contributor.author | Bharania, Punam | - |
dc.contributor.author | Campbell, Fiona | - |
dc.contributor.author | Paff, Melanie | - |
dc.contributor.author | Theodore, Dickens | - |
dc.date.accessioned | 2022-09-06T01:40:17Z | - |
dc.date.available | 2022-09-06T01:40:17Z | - |
dc.date.issued | 20220625 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.issn | 1600-0641 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61422 | - |
dc.description.abstract | Background and aims: Bepirovirsen (BPV; GSK3228836) is an antisense oligonucleotide shown to induce a reduction in hepatitis B surface antigen (HBsAg), and in some cases transient HBsAg seroclearance, following 4 weeks (wks) treatment with a favourable safety profile in a phase 2a study in patients ( pts) with chronic hepatitis B (CHB) infection. B-Clear is a phase 2b trial (NCT04449029) assessing the efficacy and safety of 12 or 24 wks BPV treatment in pts with CHB on-stable nucleos (t)ide analogue (NA) treatment or not on-NA therapy at study start. The study is ongoing; here we present interim results through the end of BPV treatment (EoT) for pts not on NA therapy. Method: Multicentre, randomised, partial-blind (investigator unblinded), parallel-cohort study in pts with CHB. Pts required HBsAg >100 IU/ml, HBV DNA <90 IU/ml and alanine aminotransferase ≤2× upper limit of normal. Pts were randomised (3:3:3:1) to 1 of 4 treatment arms, with treatment administered weekly with (w/) or without (w/o) loading doses (LD) on Days 4 and 11: 1. BPV 300 mg w/LD for 24 wks; 2. BPV 300 mg w/LD for 12 wks then 150 mg for 12 wks; 3. BPV 300 mg w/LD for 12 wks then placebo (PBO) for 12 wks; 4. PBO for 12 wks then BPV 300 mg w/o LD for 12 wks. Pts were stratified by baseline hepatitis B e antigen (HBeAg; positive/negative) and HBsAg level (≤3 or >3 log10 IU/ml). Primary end point: proportion of pts achieving HBsAg <lower limit of quantification (LLOQ) and HBV DNA <LLOQ sustained for 24 wks without rescue medication after planned BPV EoT. Secondary end points reported here: proportion of pts achieving HBsAg <LLOQ and HBV DNA <LLOQ by BPV EoT. Safety was assessed via adverse event (AE) monitoring. Results: 227 pts (73% male, 52% Asian, 69% HBeAg negative, 28% HBsAg ≤3 log10 IU/ml) were included in the intent-to-treat population (68, 68, 68 and 23 pts, respectively, in arms 1–4); 12 pts (5%) discontinued treatment. At EoT, 28%, 17%, 9% and 14% pts had HBsAg <LLOQ and HBV DNA <LLOQ in arms 1–4, respectively. HBsAg response data are shown in Figure. Overall, serious AEs (SAEs) were reported in 3% pts and treatment-related SAEs in <1% pts. No clinically meaningful differences in AEs across treatment arms. Conclusion: 24 wks of 300 mg BPV resulted in HBsAg <LLOQ and HBV DNA <LLOQ in 28% pts at EoT; the durability of this response is being assessed. There were no safety signals to preclude further development. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study | - |
dc.type | Conference | - |
dc.identifier.doi | 10.1016/S0168-8278(22)00444-5 | - |
dc.citation.title | Journal of Hepatology | - |
dc.citation.startPage | S13 | - |
dc.citation.endPage | S13 | - |
dc.citation.conferenceName | The International Liver Congress 2022 | - |
dc.citation.conferencePlace | 영국 | - |
dc.citation.conferencePlace | London, UK | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.